WisdomTree.eu
+44 (0) 207 448 4330
Document Date: 30/09/2026

WDNA WisdomTree BioRevolution UCITS ETF - USD Acc

Investment Objective

The WisdomTree BioRevolution UCITS ETF (the "Fund") seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution ESG Screened Index (the "Index").

Index Description

The index is designed to track performance of companies that will be significantly transformed by advancements in genetics and biotechnology (including COVID-19 vaccines). The index excludes companies which do not meet WisdomTree's ESG (environmental, social and governance) criteria. To be included in the Index, companies must meet certain risk management criteria, as well as minimum liquidity requirements, WisdomTree's ESG screen and be involved in BioRevolution activities. The key sectors listed below are used as guidelines to determine if a company is primarily involved in BioRevolution Activities, including Human health, Agriculture & Food, Materials, Chemicals, & Energy and Biological Machines & Interfaces.
The Index is rebalanced on a semi-annual basis.

Performance (Net of fees) (USD)

Name	QTR	YTD	1-Year	3-Year	Inception Date
WDNA NAV	16.44%	42.29%	56.85%	18.84%	2.30%
WisdomTree BioRevolution ESG Screened Net Return Index	16.59%	42.81%	57.61%	19.28%	2.65%

Source: WisdomTree UK, Bloomberg, as of 30/09/2026. Performance for the fund and the Index is shown in the listing currency. Past performance is not a reliable indicator of future results. Performance of less than one year is cumulative.

Product Information

Asset Class	Equities
Benchmark	WisdomTree BioRevolution ESG Screened Net Return Index
Replication Method	Physical, Fully Replicated
Total Expense Ratio	0.45%
Base Currency	USD
Use of Income	Accumulating
Distribution Frequency	N/A
Inception Date	06/12/2021
Financial Year End	31 December
UCITS Compliant	Yes
ISA Eligible	Yes
SIPP Eligible	Yes
PEA Eligible	No
Registration	AT, CH, DE, DK, ES, FI, FR, GB, IE, IT, LU, NL, NO, SE
Manager	WisdomTree Management Ltd.
Investment Manager	Keyridge Asset Management Limited
Administrator	BNY Mellon Fund Services (Ireland) Designated Activity Company
Custodian	The Bank of New York Mellon SA/NV, Dublin Branch

Index Information

Index	WisdomTree BioRevolution ESG Screened Net Return Index
Index Provider	WisdomTree, Inc.
Index Currency	USD
Index Bloomberg Code	WTEDNAN

ESG Characteristics

SFDR Disclosure	SFDR Article 8

This document is marketing material. Investors should read the prospectus of the Issuer ("Prospectus") and the key information document ("KID") before investing and should refer to the section of the Prospectus titled 'Risk Factors' for further details of risks associated with an investment in this product.

Calendar Year Performance (Net of fees)

Name	2022	2023	2024	2025
WisdomTree BioRevolution UCITS ETF - USD Acc	-26.03%	-2.73%	-14.21%	22.34%
WisdomTree BioRevolution ESG Screened Net Return Index	-25.80%	-2.38%	-13.95%	22.73%

Source: WisdomTree UK, Bloomberg, as of 30/09/2026. Performance for the fund and the Index is shown in the listing currency. Past performance is not a reliable indicator of future results. Performance of less than one year is cumulative.

Rolling 12-month performance (Net of fees)


Name	Sep'2022-Sep'2023	Sep'2023-Sep'2024	Sep'2024-Sep'2025	Sep'2025-Sep'2026
WisdomTree BioRevolution UCITS ETF - USD Acc	-10.37%	10.02%	-2.76%	56.85%
WisdomTree BioRevolution ESG Screened Net Return Index	-10.12%	10.43%	-2.50%	57.61%

Source: WisdomTree UK, Bloomberg, as of 30/09/2026. Performance for the fund and the Index is shown in the listing currency. Past performance is not a reliable indicator of future results. Performance of less than one year is cumulative.


This document is marketing material. Investors should read the prospectus of the Issuer ("Prospectus") and the key information document ("KID") before investing and should refer to the section of the Prospectus titled 'Risk Factors' for further details of risks associated with an investment in this product.

Top 10 Holdings (% Weight)	
Moderna Inc	9.92%
Twist Bioscience Corp	9.70%
10X Genomics Inc-Class A	3.71%
Eli Lilly & Co	3.43%
Natera Inc	3.07%
Tempus Ai Inc	2.80%
Johnson & Johnson	2.67%
Iovance Biotherapeutics Inc	2.38%
United Therapeutics Corp	2.16%
Immunome Inc	1.99%

Fund Sector Exposure (% Weight)



Top 10 Countries (% Weight)



NB: Sources for all tables/charts on these pages: WisdomTree UK, Bloomberg. All data as of 30/09/2026

Listing Information

Exchange	Trading Currency	Exchange Ticker	Bloomberg Code	RIC	SEDOL	ISIN	WKN	Listing Date
LSE	USD	WDNA	WDNA LN	WDNA.L	BMH8657	IE000O8KMPM1	A3CY21	09/12/2021
LSE	GBx	WBIO	WBIO LN	WTWBIO.L	BMH8668	IE000O8KMPM1	A3CY21	09/12/2021
Xetra	EUR	WRNA	WRNA GY	WRNA.DE	BMH8679	IE000O8KMPM1	A3CY21	09/12/2021
Borsa Italiana	EUR	WDNA	WDNA IM	WDNA.MI	BMH8680	IE000O8KMPM1	A3CY21	17/01/2022
BMV	MXN	WDNA1	WDNA1N MM	WDNA.MX	BMDKSY0	IE000O8KMPM1	A3CY21	26/12/2022
SIX	USD	WDNA	WDNA SW	WDNA.S	BPZK4H4	IE000O8KMPM1	A3CY21	23/01/2023

This document is marketing material. Investors should read the prospectus of the Issuer ("Prospectus") and the key information document ("KID") before investing and should refer to the section of the Prospectus titled 'Risk Factors' for further details of risks associated with an investment in this product.

Potential Benefits

The Fund offers access through direct investment in publicly listed companies, which will be significantly transformed by advancements in genetics and biotechnology (including COVID-19 vaccines).

Focused exposure to businesses that have multi-sector genetics and biotechnology investments with strong growth characteristics and which meet WisdomTree's ESG (environmental, social and governance) criteria.

The research for the selection of companies in the Index and, subsequently, the Fund, is conducted by expert in the BioRevolution space, ensuring the portfolio remains focused and relevant.

The ETF is physically backed and UCITS compliant.

Potential Risks

Although the Index was created to select companies with a relatively higher exposure to BioRevolution activities, there is no guarantee this objective will be achieved.

An investment in equities may experience high volatility and should be considered as a long-term investment.

Higher growth companies such as those that play a part in megatrends tend to trade at higher valuations. The investor should consider the risk that comes with higher valuations as part of any investment decision.

Investment risk may be concentrated in specific sectors, countries, companies or currencies.

This list does not cover all risks-further risks are disclosed in the KID/KIID and Prospectus.

Glossary

Dividend Weighted Index: an index that determines the weight of its constituents using the dividends paid by the security rather than another variable (the most common is Market Cap weighted indices).

Fully Replicated: assets are invested in securities that match the constituents of the relevant index, in the same proportion.

Fundamentally Weighted Index: an index that weights securities on the basis of factors such as dividends or earnings.

Large Cap, Mid Cap and Small Cap: refers to market capitalisation and is calculated by multiplying the price of a stock by the number of shares outstanding.

Listing currency: the trading currency on the exchange.

Physical (Optimised): assets are predominantly invested in securities that are constituents of the index, but may also hold securities whose characteristics closely resemble the characteristics of the index.

Physically Backed: securities held by the fund are the actual securities not a derivative.

Rebalance: An index is created by applying a certain set of selection and weighting rules of countries, sectors and stocks at a certain frequency. A Rebalance is when WisdomTree re-applies its rules based selection and weighting process.

Rebalance Frequency: The frequency by which the constituents of the index are screened and their weights changed.

Replication Method: the method by which the fund gets exposure to the benchmark index.

Share class currency or the "NAV currency": The currency that the fund's NAV is issued in.

Total Expense Ratio (TER): A measure of the total costs associated with managing and operating a fund. The TER consists primarily of management fees plus other expenses such as trustee, custody and operating expenses. It does not cover the swap fee. The TER is expressed as a percentage of the fund's total net asset value.

Disclaimer

IMPORTANT INFORMATION

Marketing communications issued in the European Economic Area ("EEA") & Switzerland: This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

Marketing communications issued in jurisdictions outside of the EEA, except Switzerland: This document has been issued and approved by WisdomTree UK Limited or Atlantic House Investments Limited, which are both authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited, WisdomTree UK Limited and Atlantic House Investments Limited are referred to as "WisdomTree" (as applicable) throughout. Our Conflicts of Interest Policy and Inventory are available on request.

This marketing communication is intended for all investors; however, the WisdomTree products described in this document and related materials may be restricted in certain jurisdictions and may only be available to particular categories of investors in accordance with applicable laws and regulations. Where a product is not authorised or its distribution is restricted in your jurisdiction, it is the responsibility of any person or entity in possession of this information to inform themselves of, and comply with, all relevant restrictions. Before making any investment, investors should seek appropriate legal, regulatory, tax and investment advice to assess the suitability and implications of investing in these products. Information about WisdomTree products is available at wisdomtree.eu. WisdomTree does not offer investment advice tailored to individual circumstances. Past performance is not a reliable indicator of future performance. Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment.

This marketing communication should be read in conjunction with the relevant WisdomTree products' Prospectus, Key Investor Information Document ("KIID"), Key Information Document ("PRIIPS KID") as relevant. In particular, investors should carefully read the specific risks detailed under the section entitled 'Risk and Reward Profile' in the KIID, 'What are the risks and what could I get in return?' in PRIIPs KID and under the section entitled 'Risk Factors' in the Prospectus of the Issuer for further details of risks associated with an investment in the product(s) detailed herein. Further information regarding the WisdomTree exchange-traded product(s) detailed herein, such as a detailed list of the underlying investments and the indicative net asset value, can be obtained by visiting the WisdomTree website at (www.wisdomtree.eu).

An investment in WisdomTree exchange-traded products ("ETPs") is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. An investment in WisdomTree funds is dependent on the performance of the underlying investments, less costs.

Both WisdomTree ETPs and funds involve numerous risks including among others, general market risks relating to any relevant underlying index, credit risks on the provider of index swaps utilised in ETPs, exchange rate risks, interest rate risks, inflationary risks, liquidity risks, derivatives risk and legal and regulatory risks.

The information contained in this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the issuers or their products are authorised or registered for distribution and where no prospectus of any of the issuers has been filed with any securities commission or regulatory authority. No document or information in this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

This document may contain independent market commentary prepared by WisdomTree based on publicly available information. Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not warrant or guarantee its accuracy or correctness. Any third party data providers used to source the information in this document make no warranties or representation of any kind relating to such data. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. WisdomTree strongly recommends that you do not place undue reliance on these forward-looking statements.

Certain funds referred to in this document are issued by WisdomTree Issuer ICAV ("WT Issuer"). WT Issuer is an open-ended, umbrella-type Irish Collective Asset-management Vehicle with segregated liability between sub-funds and is authorised by the Central Bank of Ireland ("CBI") as an Undertaking for Collective Investment in Transferable Securities ("UCITS") under Irish law. Each fund is represented by a separate class of shares (the "Shares") issued by WT Issuer.

The Fund is described in a Key Information Document (KID) or Key Investor Information Document (KIID) for UK investors, and the prospectus of WT Issuer ("WT Prospectus"). A copy of the WT Prospectus and the KID / KIID is available, for EEA/UK only, in English at www.wisdomtree.eu. Where required under national rules, the KID will also be available in the local language of the relevant EEA Member State. Investors should read the WT Prospectus before investing and should refer to the section of the WT Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the Shares.

The summary of investor rights associated with an investment in the fund is available in English on WisdomTree Europe's website. WisdomTree Management Limited may decide to terminate the arrangements made for the marketing of its collective investment undertakings. In such circumstances, shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the fund free of any charges or deductions for at least 30 working days from the date of such notification.

Additional Information

For Investors in Switzerland: This document constitutes an advertisement of the financial product(s) mentioned herein.
The prospectus (in English only) and the key investor information documents (KID) (in German, French and Italian) are available from WisdomTree's website: https://www.wisdomtree.eu/en-ch/resource-library/prospectus-and-regulatory-reports
For WisdomTree UCITS products only: the representative and paying agent of the ETPs in Switzerland is Société Générale Paris, Zurich Branch, Talacker 50, PO Box 5070, 8021 Zurich, Switzerland. The prospectus, the key investor information documents (KIID), the articles of association and the annual and semi-annual reports of the sub-funds are available free of charge from the representative and paying agent. As regards distribution in Switzerland, the place of jurisdiction and performance is at the registered seat of the representative and paying agent. Some of the sub-funds referred to in this document may not have been registered with the Swiss Financial Market Supervisory Authority ("FINMA"). In Switzerland, such sub-funds that have not been registered with FINMA may only be available to Qualified Investors.

FOR INVESTORS IN FRANCE:
Further information regarding the WisdomTree exchange-traded product(s) detailed herein, such as a detailed list of the underlying investments and the indicative net asset value, can be obtained by visiting the WisdomTree website at (https://www.wisdomtree.eu).
The product is intended for retail investors who: (i) can withstand capital loss, are not seeking to preserve capital and are not seeking a capital guarantee; (ii) have specific knowledge or experience in investing in similar products and in the financial markets; and (iii) are looking for a product that provides exposure to the performance of the underlying asset(s) and have an investment horizon in line with the recommended holding period indicated in the KID.
In addition, the indicative net asset value is shown on the Reuters and Bloomberg pages of the product and may also be mentioned on the websites of the product's listing venues.
Units in a listed exchange-traded product purchased on the secondary market generally cannot be sold directly back to the listed exchange-traded product. For investors who are not authorised participants, the purchase and sale of units must be done on a secondary market with the help of an intermediary (e.g., a broker), and may therefore be subject to additional fees and taxes. In addition, it is possible that investors may pay more than the current net asset value when purchasing units and receive less than the current net asset value when selling them.
Investors should carefully read the specific risks detailed under the section entitled 'What are the risks and what could I get in return?' in the Key Information Document for Packaged Retail and Insurance-based Investment Products (PRIIPs KID) and under the section entitled 'Risk Factors' in the Prospectus of the Issuer for further details of risks associated with an investment in the product detailed herein.
Investors are advised that the prospectus is available in French and English.
This document is a promotional material relating to the financial product(s) mentioned herein. The prospectus and the Key Investor Information Document (KIID) are available on the WisdomTree website: https://www.wisdomtree.eu/resource-library/prospectus-and-regulatory-reports
The distribution of the Prospectus and the offering, sale and delivery of Shares in other jurisdictions may be restricted by law. WT Issuer is a UCITS governed by Irish legislation, and approved by the Central Bank of Ireland as UCITS compliant with European regulations although it may not have to comply with the same rules as those applicable to a similar product approved in France.
The Fund has been registered for marketing in France by the Financial Markets Authority (Autorité des Marchés Financiers) and may be distributed to investors in France. Copies of all documents (i.e. the Prospectus, any supplements or addenda thereto, the Key Information Document, the latest annual reports and the instrument of incorporation) are available in France, free of charge at the French centralizing agent, Societe Generale at 29, Boulevard Haussmann, 75009, Paris, France. Any subscription for Shares of the Fund will be made on the basis of the terms of the prospectus and any supplements or addenda thereto.
Investors should note that, relative to the expectations of the Autorité des Marchés Financiers, this UCITS presents disproportionate communication on the consideration of non-financial criteria in its management.